Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models

References

• 1 Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 64(1), 9–29 (2014).
  MedlineGoogle Scholar
• 2 Islam KM, Jiang X, Anggondowati T, Lin G, Ganti AK. Comorbidity and survival in lung cancer patients. Cancer Epidemiol. Biomarkers Prev. 24(7), 1079–1085 (2015).
  MedlineGoogle Scholar
• 3 Chen J, Solomides C, Parekh H, Simpkins F, Simpkins H. Cisplatin resistance in human cervical, ovarian and lung cancer cells. Cancer Chemother. Pharmacol. 75(6), 1217–1227 (2015).
  Medline CASGoogle Scholar
• 4 Ganguly A, Cabral F. New insights into mechanisms of resistance to microtubule inhibitors. Biochim. Biophys. Acta 1816(2), 164–171 (2011).
  Medline CASGoogle Scholar
• 5 Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother. Pharmacol. 75(4), 659–670 (2015).
  Medline CASGoogle Scholar
• 6 Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin. Adv. Hematol. Oncol. 6(6), 455–467 (2008).
  MedlineGoogle Scholar
• 7 Huang M, Shen A, Ding J, Geng M. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol. Sci. 35(1), 41–50 (2014).
  MedlineGoogle Scholar
• 8 Silva P, Barbosa J, Nascimento AV, Faria J, Reis R, Bousbaa H. Monitoring the fidelity of mitotic chromosome segregation by the spindle assembly checkpoint. Cell Prolif. 44(5), 391–400 (2011).
  Medline CASGoogle Scholar
• 9 Barbosa J, Nascimento AV, Faria J, Silva P, Bousbaa H. The spindle assembly checkpoint: perspectives in tumorigenesis and cancer therapy. Front. Biol. 6(2), 147–155 (2011).
  CASGoogle Scholar
• 10 Kato T, Daigo Y, Aragaki M et al. Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients. Lung Cancer 74(1), 124–131 (2011).
  MedlineGoogle Scholar
• 11 Teixeira JH, Silva P, Faria J et al. Clinicopathologic significance of BubR1 and Mad2 overexpression in oral cancer. Oral Dis. 21(6), 713–720 (2015).
  Medline CASGoogle Scholar
• 12 Kim Y, Choi JW, Lee JH, Kim YS. MAD2 and CDC20 are upregulated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the uterine cervix. Int. J. Gynecol. Pathol. 33(5), 517–523 (2014).
  Medline CASGoogle Scholar
• 13 Choi JW, Kim Y, Lee JH, Kim YS. High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer. Virchows Arch. 463(5), 681–687 (2013).
  MedlineGoogle Scholar
• 14 Nascimento AV, Singh A, Bousbaa H, Ferreira D, Sarmento B, Amiji MM. Mad2 checkpoint gene silencing using epidermal growth factor receptor-targeted chitosan nanoparticles in non-small cell lung cancer model. Mol. Pharm. 11(10), 3515–3527 (2014).
  Medline CASGoogle Scholar
• 15 Burgess A, Rasouli M, Rogers S. Stressing mitosis to death. Front. Oncol. 4, 140 (2014).
  MedlineGoogle Scholar
• 16 Michel L, Diaz-Rodriguez E, Narayan G, Hernando E, Murty VV, Benezra R. Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc. Natl Acad. Sci. USA 101(13), 4459–4464 (2004).
  Medline CASGoogle Scholar
• 17 Borna H, Imani S, Iman M, Azimzadeh Jamalkandi S. Therapeutic face of RNAi: in vivo challenges. Expert Opin. Biol. Ther. 15(2), 269–285 (2015).
  Medline CASGoogle Scholar
• 18 Haussecker D. Current issues of RNAi therapeutics delivery and development. J. Control. Release 195, 49–54 (2014).
  Medline CASGoogle Scholar
• 19 Chaturvedi K, Ganguly K, Kulkarni AR et al. Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review. Expert Opin. Drug Deliv. 8(11), 1455–1468 (2011).
  Medline CASGoogle Scholar
• 20 Eloy JO, Petrilli R, Lopez RF, Lee RJ. ‘Stimuli-responsive nanoparticles for siRNA delivery’. Curr. Pharm. Des. 21(29), 4131–4144 (2015).
  Medline CASGoogle Scholar
• 21 Hattori Y, Nakamura A, Arai S, Kawano K, Maitani Y, Yonemochi E. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes. J. Liposome Res. 25(4), 1–8 (2015).
  MedlineGoogle Scholar
• 22 Kim MJ, Park JS, Lee SJ et al. Notch1 targeting siRNA delivery nanoparticles for rheumatoid arthritis therapy. J. Control. Release 216, 140–148 (2015).
  Medline CASGoogle Scholar
• 23 Ngamcherdtrakul W, Morry J, Gu S et al. Cationic polymer modified mesoporous silica nanoparticles for targeted SiRNA delivery to HER2+ breast cancer. Adv. Funct. Mater. 25(18), 2646–2659 (2015).
  Medline CASGoogle Scholar
• 24 Yhee JY, Song S, Lee SJ et al. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance. J. Control. Release 198, 1–9 (2015).
  Medline CASGoogle Scholar
• 25 Zhao Y, Li H, Wu R et al. Antitumor effects of oncolytic adenovirus-carrying siRNA targeting potential oncogene EphA3. PLoS ONE 10(5), e0126726 (2015).
  MedlineGoogle Scholar
• 26 Andrade F, Antunes F, Nascimento AV et al. Chitosan formulations as carriers for therapeutic proteins. Curr. Drug Disc. Technol. 8(3), 157–172 (2011).
  Medline CASGoogle Scholar
• 27 Sarmento B, Das Neves J. Chitosan-Based Systems For Biopharmaceuticals: Delivery, Targeting And Polymer Therapeutics. John Wiley & Sons (2012).
  Google Scholar
• 28 Croisier F, Jérôme C. Chitosan-based biomaterials for tissue engineering. Eur. Polym. J. 49(4), 780–792 (2013).
  CASGoogle Scholar
• 29 Smith J, Wood E, Dornish M. Effect of chitosan on epithelial cell tight junctions. Pharm. Res. 21(1), 43–49 (2004).
  Medline CASGoogle Scholar
• 30 Rai M. Natural antimicrobials in food safety and quality. College Rutgers University. CABI (2011).
  Google Scholar
• 31 Kim S-K. Chitin And Chitosan Derivatives: Advances In Drug Discovery And Developments. CRC Press, USA, FL (2013).
  Google Scholar
• 32 Lai WF, Lin MC. Nucleic acid delivery with chitosan and its derivatives. J. Control. Release 134(3), 158–168 (2009).
  Medline CASGoogle Scholar
• 33 Nehoff H, Parayath NN, Domanovitch L, Taurin S, Greish K. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. Int. J. Nanomed. 9, 2539–2555 (2014).
  MedlineGoogle Scholar
• 34 Prabhakar U, Maeda H, Jain RK et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73(8), 2412–2417 (2013).
  Medline CASGoogle Scholar
• 35 Zhong Y, Meng F, Deng C, Zhong Z. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. Biomacromolecules 15(6), 1955–1969 (2014).
  Medline CASGoogle Scholar
• 36 Gaber R, Watermann I, Kugler C et al. Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC. Diagn. Pathol. 9, 165 (2014).
  MedlineGoogle Scholar
• 37 Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 41(Suppl. 1), S29–S42 (2003).
  MedlineGoogle Scholar
• 38 Ganta S, Singh A, Patel NR et al. Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer. Pharm. Res. 31(9), 2490–2502 (2014).
  Medline CASGoogle Scholar
• 39 Milane L, Duan Z, Amiji M. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS ONE 6(9), e24075 (2011).
  Medline CASGoogle Scholar
• 40 Singh A, Xu J, Mattheolabakis G, Amiji M. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model. Nanomedicine doi:10.1016/j.nano.2015.11.010 (2015) (Epub ahead of print).
  Google Scholar
• 41 Xu J, Gattacceca F, Amiji M. Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin nanoparticles following systemic administration in pancreatic tumor-bearing mice. Mol. Pharm. 10(5), 2031–2044 (2013).
  Medline CASGoogle Scholar
• 42 Rusnak DW, Alligood KJ, Mullin RJ et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif. 40(4), 580–594 (2007).
  Medline CASGoogle Scholar
• 43 Schafer A, Pahnke A, Schaffert D et al. Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation. Hum. Gene Ther. 22(12), 1463–1473 (2011).
  Medline CASGoogle Scholar
• 44 Li Z, Zhao R, Wu X et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 19(14), 1978–1985 (2005).
  Medline CASGoogle Scholar
• 45 Turner PV, Brabb T, Pekow C, Vasbinder MA. Administration of substances to laboratory animals: routes of administration and factors to consider. J. Am. Assoc. Lab. Anim. Sci. 50(5), 600 (2011).
  Medline CASGoogle Scholar
• 46 Li J, Makrigiorgos GM. Anti-primer quenching-based real-time PCR for simplex or multiplex DNA quantification and single-nucleotide polymorphism genotyping. Nat. Protoc. 2(1), 50–58 (2007).
  Medline CASGoogle Scholar
• 47 Ganesh S, Iyer AK, Gattacceca F, Morrissey DV, Amiji MM. In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. J. Control. Release 172(3), 699–706 (2013).
  Medline CASGoogle Scholar
• 48 Holder DJ. Comments on Nedelman and Jia's extension of Satterthwaite's approximation applied to pharmacokinetics. J. Biopharm. Stat. 11(1–2), 75–79 (2001).
  Medline CASGoogle Scholar
• 49 Nedelman JR, Jia X. An extension of Satterthwaite's approximation applied to pharmacokinetics. J. Biopharm. Stat. 8(2), 317–328 (1998).
  Medline CASGoogle Scholar
• 50 Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv. Drug Del. Rev. 62(1), 3–11 (2010).
  Medline CASGoogle Scholar
• 51 Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5(4), 505–515 (2008).
  Medline CASGoogle Scholar
• 52 Rao J, Dragulescu-Andrasi A, Yao H. Fluorescence imaging in vivo: recent advances. Curr. Opin. Biotechnol. 18(1), 17–25 (2007).
  Medline CASGoogle Scholar
• 53 Zhang X, Bloch S, Akers W, Achilefu S. Near-infrared molecular probes for in vivo imaging. Curr. Protoc. Cytom. 12(Unit 12), 27 (2012).
  Medline CASGoogle Scholar
• 54 Yi X, Wang F, Qin W, Yang X, Yuan J. Near-infrared fluorescent probes in cancer imaging and therapy: an emerging field. Int. J. Nanomedicine 9, 1347–1365 (2014).
  MedlineGoogle Scholar
• 55 Luo S, Zhang E, Su Y, Cheng T, Shi C. A review of NIR dyes in cancer targeting and imaging. Biomaterials 32(29), 7127–7138 (2011).
  Medline CASGoogle Scholar
• 56 Qi L, Xu Z. In vivo antitumor activity of chitosan nanoparticles. Bioorg. Med. Chem. Lett. 16(16), 4243–4245 (2006).
  Medline CASGoogle Scholar
• 57 Jayakumar R, Muzzarelli R, Prabaharan M. Chitosan for Biomaterials I. Springer-Verlag, Berlin, Heidelberg, Germany (2011).
  Google Scholar
• 58 Wang J, Sui M, Fan W. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr. Drug Metab. 11(2), 129–141 (2010).
  Medline CASGoogle Scholar
• 59 Leucuta SE. Subcellular drug targeting, pharmacokinetics and bioavailability. J. Drug Target. 22(2), 95–115 (2014).
  Medline CASGoogle Scholar
• 60 Yamashita F, Hashida M. Pharmacokinetic considerations for targeted drug delivery. Adv. Drug Deliv. Rev. 65(1), 139–147 (2013).
  Medline CASGoogle Scholar
• 61 Cabral H, Matsumoto Y, Mizuno K et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 6(12), 815–823 (2011).
  Medline CASGoogle Scholar
• 62 Choi KY, Min KH, Yoon HY et al. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials 32(7), 1880–1889 (2011).
  Medline CASGoogle Scholar
• 63 Tobin LA, Xie Y, Tsokos M et al. Pegylated siRNA-loaded calcium phosphate nanoparticle-driven amplification of cancer cell internalization in vivo. Biomaterials 34(12), 2980–2990 (2013).
  Medline CASGoogle Scholar
• 64 Chen S, Yang K, Tuguntaev RG et al. Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance. Nanomed. Nanotechnol. Biol. Med. doi:10.1016/j.nano.2015.10.020 (2015) (Epub ahead of print).
  Google Scholar
• 65 Ganta S, Singh A, Kulkarni P et al. EGFR targeted theranostic nanoemulsion for image-guided ovarian cancer therapy. Pharm. Res. 32(8), 2753–2763 (2015).
  Medline CASGoogle Scholar
• 66 Talekar M, Trivedi M, Shah P et al. Combination wt-p53 and MicroRNA-125b transfection in a genetically-engineered lung cancer model using dual CD44/EGFR targeting nanoparticles. Mol. Ther. doi:10.1038/mt.2015.225 (2015) (Epub ahead of print).
  MedlineGoogle Scholar